Their RNASeq data indicated that MSI‐2 acts as a pleiotropic inhibitor of known intestinal tumor suppressors, including Lrig1, Bmpr1a, Cdkn1a, and Pten. This evidence concerns the gene CDKN1A and neoplasm.